Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
Orphazyme tries its luck
Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…
Upcoming events – Achillion fishes for complements as Aquestive tackles ALS
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.